First Quarter 2018 Investor Presentation
Investor Presentation
First three months of 2018
Slide 81
SaxendaⓇ has rapidly grown value market share, but market
development efforts are required to expand the market
Despite strong SaxendaⓇ growth, US obesity
care market remains small at USD ~740 million
Novo Nordisk is investing in overcoming the
barriers preventing effective obesity care
Current state
Key initiatives
SaxendaⓇ
Other branded AOM
Generic AOM
TRX market share
mUSD/value market share
100%
800
7%
Mindset
80%
600
43%
60%
82%
400
40%
Few
prescribers
engaged
200
50%
20%
0%
Limited
patient
Volume
Value
access
AOM: Anti-obesity medication; TRx: Total prescriptions
Source: IQVIA NPA and NSP moving annual total through February 2018
changing
diabetes®
Acute weight loss focus
with SaxendaⓇ stay-
time ~5 months
Advocate for chronic
treatment through
partnerships
Less than 3,000
physicians write ≥10
AOM prescriptions per
month
Only 2 in 5 of ~95
million adults with
obesity have access to
reimbursed medication
Launch obesity
educator programme
Obtain Medicare
coverage
through support of
"Treat and Reduce
Obesity Act"
novo nordiskView entire presentation